| Literature DB >> 33505144 |
Ai-Lin Wei1, Mao Li1, Guo-Qing Li2, Xuan Wang2, Wei-Ming Hu1, Zhen-Lu Li1, Jue Yuan1, Hong-Ying Liu1, Li-Li Zhou1, Ka Li3, Ang Li4, Mei Rosemary Fu5.
Abstract
BACKGROUND: Microbiota profiles differ between patients with pancreatic cancer and healthy people, and understanding these differences may help in early detection of pancreatic cancer. Saliva sampling is an easy and cost-effective way to determine microbiota profiles compared to fecal and tissue sample collection. AIM: To investigate the saliva microbiome distribution in patients with pancreatic adenocarcinoma (PDAC) and the role of oral microbiota profiles in detection and risk prediction of pancreatic cancer.Entities:
Keywords: 16s rRNA; Cancer detection; Dysbiosis; High-throughput sequencing; Oral microbiota; Pancreatic cancer
Mesh:
Substances:
Year: 2020 PMID: 33505144 PMCID: PMC7789059 DOI: 10.3748/wjg.v26.i48.7679
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Demographic characteristics of participants
|
|
|
|
|
| Age, average ± standard error | 61.17 ± 1.79 | 64.64 ± 1.04 | 0.098 |
| Gender, | |||
| Male | 24 (59) | 50 (72) | 0.132 |
| Female | 17 (41) | 19 (28) | |
| BMI, average ± standard error | 22.76 ± 0.94 | 24.44 ± 0.39 | < 0.0001 |
| Smoking history, | 17 (41) | 37 (54) | 0.217 |
| Alcohol consumption, | 16 (39) | 30 (43) | 0.647 |
| Dietary habit, | |||
| Oily and fatty food | 25 (61) | 21 (31) | 0.002 |
| Salty food | 6 (15) | 8 (11) | 0.664 |
| Light diet | 10 (24) | 40 (58) | 0.001 |
| Chronic disease, | |||
| Hypertension | 1 (2) | 15 (22) | 0.006 |
| Type II diabetes | 2 (5) | 6 (9) | 0.714 |
| Both | 3 (7) | 5 (7) | 1.000 |
| Loss of weight, | 23 (56) | 3 (4) | 0.0001 |
| Primary cancer site, | |||
| Head | 31 (76) | NA | NA |
| Body and tail | 10 | ||
| Surgery, | |||
| Pancreaticoduodenectomy | 14 (34) | NA | NA |
| Distal pancreatectomy | 6 (15) | ||
| Palliative intervention techniques | 21 (51) | ||
| AJCC staging | NA | NA | |
| I-IIB | 20 (49) | ||
| III-IV | 21 |
AJCC: American Joint Commission on Cancer; BMI: Body mass index; PDAC: Pancreatic adenocarcinoma.
Figure 1Microbial profiles of two groups. Venn diagram showing shared and unique operational taxonomic units (OTUs) at 97% identity among pancreatic adenocarcinoma (PDAC) group (n = 41) and healthy controls (HC) group (n = 69). PDAC group is blue; HC group is green. OTUs (690) are shared by two groups. Unique OTUs of 231 and 389 were found in PDAC and HC, respectively.
α-diversity indices of two groups
|
|
|
|
|
| Shannon | 5.14 ± 0.67 | 5.67 ± 0.51 | 0.0001 |
| Simpson | 0.90 ± 0.08 | 0.95 ± 0.02 | 0.0001 |
| Chao1 | 423.48 ± 55.69 | 295.00 ± 54.05 | 0.0001 |
| ACE | 424.00 ± 55.72 | 293.97 ± 50.09 | 0.0001 |
PDAC: Pancreatic adenocarcinoma.
Figure 2Linear discriminant analysis effect size and latent dirichlet allocation analysis based on operational taxonomic units. A: Shows a list of specific oral bacteria that enable discrimination between pancreatic adenocarcinoma (PDAC) patients and healthy controls (HC). Differences in oral microbial communities between PDAC patients and HC. The horizontal line with red and green denotes the means of the HC and PDAC groups, respectively; B: Resectable PDAC (rPDAC) and unresectable PDAC (unrPDAC). Differences in oral microbial communities between rPDAC group and unrPDAC. The horizontal line with red and green denotes the means of the rPDAC and unrPDAC groups, respectively.
Flora abundance differences in pancreatic adenocarcinoma patients with symptomatic phenotype
|
|
|
|
|
|
| Bloating |
| 412.0 ± 394.3 | 660.4 ± 461.0 | 0.039 |
|
| 361.8 ± 184.4 | 490.0 ± 186.6 | 0.024 | |
|
| 99.3 ± 81.9 | 155.4 ± 124.1 | 0.041 | |
| Jaundice |
| 669.4 ± 384.3 | 403.2 ± 310.8 | 0.008 |
| Dark brown urine |
| 1863.8 ± 1449.2 | 1018.6 ± 766.7 | 0.035 |
| Vomiting |
| 130.3 ± 100.9 | 91.8 ± 134.4 | 0.036 |
| Diarrhea |
| 1360.3 ± 1256.6 | 3343.3± 1829.9 | 0.024 |
|
| 74.9 ± 87.2 | 130.5 ± 59.7 | 0.034 |
Oral bacteria distribution and risk of pancreatic adenocarcinoma
|
|
|
|
| |
| Healthy control group | Base outcome | |||
| PDAC group | ||||
| Age | 0.956 | 0.875 | 1.046 | 0.327 |
| BMI | 0.973 | 0.708 | 1.338 | 0.866 |
| Oily and fatty food | 0.759 | 0.122 | 4.730 | 0.768 |
|
| 5.344 | 1.282 | 22.282 | 0.021 |
|
| 0.187 | 0.055 | 0.631 | 0.007 |
|
| 0.309 | 0.100 | 0.952 | 0.041 |
|
| 0.713 | 0.357 | 1.425 | 0.338 |
|
| 6.886 | 1.423 | 33.337 | 0.016 |
|
| 4.515 | 0.444 | 45.887 | 0.203 |
|
| 1.185 | 0.513 | 2.738 | 0.691 |
|
| 0.673 | 0.298 | 1.519 | 0.341 |
|
| 0.294 | 0.084 | 1.033 | 0.056 |
|
| 1.257 | 0.467 | 3.384 | 0.650 |
|
| 1.006 | 0.335 | 3.017 | 0.576 |
BMI: Body mass index; CI: Confidence interval; PDAC: Pancreatic adenocarcinoma.
Figure 3The abundance of The relative abundance of Veillonella in pancreatic adenocarcinoma (PDAC) patients is shown by the straight, and dotted lines plot the means and medians of the relative abundance. The abundance of Veillonella showed a gradual decline in saliva samples from healthy people, resectable PDAC (rPDAC), and unresectable PDAC (unrPDAC). HC: Healthy controls.